Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

viatris limited - solifenacin succinate 5mg;   - film coated tablet - 5 mg - active: solifenacin succinate 5mg   excipient: hypromellose   iron oxide yellow lactose magnesium stearate maize starch propylene glycol purified talc titanium dioxide - solifenacin viatris is indicated for the treatment of unstable bladder with symptoms of increased urinary urgency, frequent microurination, and/or urge incontinence.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - solifenacin succinate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; hypromellose; purified water; titanium dioxide; macrogol 8000; purified talc; iron oxide red - solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; purified water; lactose monohydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - solifenacin succinate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; purified water; hypromellose; titanium dioxide; macrogol 8000; purified talc; iron oxide red - solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; purified water; maize starch; hypromellose; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Malta - angielski - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - solifenacin succinate - film-coated tablet - solifenacin succinate 5 mg - urologicals

Malta - angielski - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - solifenacin succinate - film-coated tablet - solifenacin succinate 10 mg - urologicals

Izrael - angielski - Ministry of Health

teva pharmaceutical industries ltd, israel - solifenacin succinate - tablets - solifenacin succinate 5 mg - solifenacin - solifenacin - solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Izrael - angielski - Ministry of Health

teva pharmaceutical industries ltd, israel - solifenacin succinate - tablets - solifenacin succinate 10 mg - solifenacin - solifenacin - solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - solifenacin succinate; tamsulosin hydrochloride - modified-release tablet - tamsulosin and solifenacin